PRTK - Paratek Pharmaceuticals, Inc.
| Previous Close | 3.0000 |
| Open | 3.0000 |
| Bid | 3.0700 x 900 |
| Ask | 3.0800 x 800 |
| Day's Range | 2.9976 - 3.1900 |
| 52 Week Range | 2.6600 - 7.3900 |
| Volume | 424,822 |
| Avg. Volume | 597,971 |
| Market Cap | 102.027M |
| Beta (3Y Monthly) | 1.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.8360 |
| Earnings Date | Nov 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2014-10-31 |
| 1y Target Est | 17.17 |
- Benzinga
12 Biotech Stocks Primed For A Short Squeeze
Biotech investment is fraught with risk. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts. These binary events , however, provide an opportunity for making ...
- GlobeNewswire
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that on November 29, 2019, the Company granted stock options and restricted stock units to one new employee of the Company.
- Investopedia
Penny Stocks to Buy Using Technical Analysis for December 2019
While trade relations and tax-loss selling are causes for concern, opportunities for short-term and swing traders remain abundant.
- Thomson Reuters StreetEvents
Edited Transcript of PRTK earnings conference call or presentation 12-Nov-19 9:30pm GMT
Q3 2019 Paratek Pharmaceuticals Inc Earnings Call
- Simply Wall St.
Did Changing Sentiment Drive Paratek Pharmaceuticals's (NASDAQ:PRTK) Share Price Down A Painful 79%?
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) shareholders should be happy to see the share price up 26% in the last...
- Zacks
Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Tops Revenue Estimates
Paratek (PRTK) delivered earnings and revenue surprises of 5.66% and 8.43%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Paratek Pharmaceuticals Generates Net Revenues of $3.9 Million in the Third Quarter of 2019
-- Third Quarter 2019 NUZYRA® (omadacycline) Net Sales increased 82% versus the Prior Quarter to $3.1 Million -- -- Oral-only CABP Pharmacokinetics Study Initiated-- BOSTON,.
- Zacks
Analysts Estimate Paratek Pharmaceuticals (PRTK) to Report a Decline in Earnings: What to Look Out for
Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Paratek Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12, 2019
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced the Company will host a conference call and live audio webcast on Tuesday, November 12, 2019 at 4:30 p.m. EDT to report its financial results for the quarter ended September 30, 2019 and provide a corporate update. The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com. Domestic investors wishing to participate in the call should dial: 855-327-6838 and international investors should dial: 604-235-2082.
- GlobeNewswire
Paratek Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that on October 31, 2019, the Company granted stock options and restricted stock units to three new employees of the Company.
- Benzinga
The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Oct. 31) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ...
- GlobeNewswire
Paratek Announces Top Line Results of Phase 2 Clinical Studies of Omadacycline in Urinary Tract Infections
Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced the outcome of its two exploratory Phase 2 clinical studies evaluating the efficacy and safety of its once-daily oral and intravenous (IV) modernized tetracycline omadacycline in patients with two common forms of urinary tract infections (UTI). Both studies were adaptive studies which included multiple dosage regimens of omadacycline with the objective to identify a dose regimen for further investigation that would be clinically and microbiologically effective in each of the UTI indications to be studied. The first Phase 2 study, conducted in the U.S., was designed to evaluate the efficacy, safety, tolerability and pharmacokinetics of oral-only omadacycline compared to an oral-only regimen of nitrofurantoin in female patients with cystitis, or uncomplicated urinary tract infections (uUTI).
- Zacks
Earnings Preview: Paratek Pharmaceuticals (PRTK) Q3 Earnings Expected to Decline
Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Benzinga
The Daily Biotech Pulse: Intuitive Surgical Earnings, Paratek Pulls Out European Application For Antibiotic, Amgen's Evenity In Europe
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 17) Applied Therapeutics Inc (NASDAQ: APLT ) Arrowhead ...
- GlobeNewswire
Paratek Withdraws European Marketing Authorization Application for Oral and Intravenous NUZYRA in Skin Infections and Pneumonia
Application approvable by European Medicine Agency (EMA) for skin infections based on two Phase 3 studiesEMA requesting second study in CABP to meet regulatory standards of two.
- PR Newswire
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019
52 Presentations by Coalition Members During the Annual Meeting WASHINGTON , Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...
- GlobeNewswire
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) Development Program at IDWeek 2019
BOSTON, Sept. 25, 2019 -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of.
- Zacks
Paratek Pharmaceuticals (PRTK) Catches Eye: Stock Jumps 10.2%
Paratek Pharmaceuticals (PRTK) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
- GuruFocus.com
Seth Klarman Further Increases Translate Bio Stake
Baupost leader ups bet on biotech company that focuses on genetic diseases Continue reading...
- GuruFocus.com
Baupost's Seth Klarman Dives Further Into Translate Bio
Guru adds to position in biotech company that focuses on genetic diseases Continue reading...
- Simply Wall St.
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): What Does Its Beta Value Mean For Your Portfolio?
If you own shares in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) then it's worth thinking about how it contributes to...
- GlobeNewswire
Paratek Mourns Passing of Co-founder Dr. Stuart Levy
Paratek Pharmaceuticals, Inc. (PRTK) mourns the loss of Stuart Levy, M.D., who passed way last week. Dr. Levy co-founded the company more than two decades ago along with Dr. Walter Gilbert and was instrumental in the development of Paratek’s lead antibiotic, NUZYRA® and SEYSARA®. “Stuart was a distinguished physician who was the forefront of antibiotic development and a dedicated champion for the prudent use of antibiotics,” said Evan Loh, M.D., Paratek CEO.
- GlobeNewswire
Paratek Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference
Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that the Company will present at 21st Annual H.C. Wainwright Global Investment Conference on Monday, September 9 at 11:15 a.m. ET at the Lotte New York Palace Hotel in New York. To access the live webcast of Paratek's presentation, please visit http://wsw.com/webcast/hcw5/prtk/. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics.
